Principal Investigator:
Richard B. Rosen, M.D.
Enrollment Status:
Completed
Objective:
To establish the safety and efficacy of intravitreal injections of EYE001 versus sham injections in patients with subfoveal choroidal neovascularization secondary to AMD. This is a Phase II/III randomized, double-masked, controlled, dose-ranging, multi-center comparative trial, in parallel groups.
STUDY RESULTS:
MACUGEN (Pegaptanib Sodium) treatment given every 6 weeks for up to 2 years has been shown to significantly reduce the risk of moderate vision loss in patients with all types of wet AMD. Data suggests that patients who had early wet AMD and were treated with MACUGEN had improved vision outcomes than those who started treatment later. These kinds of results highlight the importance of beginning treatment before wet AMD becomes advanced and routine activities become difficult.
For more information:
